Description
Insulin Lispro (Humalog) is a rapid-acting insulin analogue and was, in the mid-1990s, the first genetically engineered insulin analogue ever to receive approval. The structural change is minimal: in the B chain of the insulin molecule, the amino acids at positions 28 and 29 are swapped. The natural proline-lysine sequence becomes lysine-proline - hence the name Lis-Pro.
That inversion weakens exactly the contact surfaces through which insulin molecules self-associate into dimers and hexamers. Human insulin sits in the subcutaneous depot as a hexamer first and has to dissociate into monomers before it can enter the bloodstream at all. That dissociation is the bottleneck. Lispro breaks apart considerably faster and is absorbed correspondingly earlier. At the insulin receptor itself, lispro behaves like human insulin: receptor tyrosine kinase is activated, GLUT4 transporters move to the cell membrane, glucose uptake into muscle and fat tissue rises, hepatic glucose output falls, lipolysis is inhibited and protein synthesis is promoted. In parallel, insulin drives potassium out of the blood and into the cell via the sodium-potassium ATPase - an effect that, in a dosing error, becomes at least as threatening as the drop in blood glucose itself.
Pharmacokinetically the profile is sharply defined: onset after about 15 minutes, serum peak at roughly 30 to 70 minutes, maximum effect at 1 to 2 hours, total duration 3 to 5 hours. Elimination half-life after subcutaneous administration is about one hour, and absolute bioavailability in the approval data is around 55 to 77 percent. For comparison: regular human insulin needs 30 to 45 minutes to take effect and keeps acting for 6 to 8 hours. That long tail is the classic reason for late hypoglycemia and exactly the point where lispro differs.
The evidence base is old and solid. Howey et al. showed in 1994 glucose clamp work that the serum insulin peak after lispro is more than twice as high and is reached in less than half the time compared to regular human insulin. The large multicenter crossover study by the Multicenter Insulin Lispro Study Group with 1,008 participants documented in 1997 a significantly flatter postprandial glucose rise and around 12 percent fewer hypoglycemic episodes versus regular human insulin, with the largest relative advantage at night. A meta-analysis across eight studies and more than 1,400 patient-years confirmed a lower rate of severe hypoglycemia in 1998. Important for context: Ebeling et al. showed in the same period that the advantage of a fast bolus insulin evaporates if basal coverage does not match it - lispro does not replace basal insulin, it complements it.
In a research context, insulin lispro is the outlier across the entire catalogue. With practically every other compound a dosing error means an unpleasant side effect. Here it means severe hypoglycemia with seizure, unconsciousness or death within one to two hours. The dose cannot be read off a table: clinical protocols derive it from body weight, carbohydrate factor and an individual correction factor, and every one of those values is person-specific. Without blood glucose measurement before and after every administration the substance is not controllable - fast carbohydrates and, for emergencies, glucagon belong within arm’s reach.
You can order Insulin Lispro as an injectable solution at U-100 concentration (100 IU per ml), size 6 ml holding 600 IU in total.
This information is for research and educational purposes only. No medical advice.
Risks & Safety
Insulin Lispro is an approved insulin analogue that has been used clinically for decades - and is still the most dangerous substance in this catalogue. The reason is not toxicity but the steepness of the action profile: the therapeutic window is extremely narrow, and an error of a few units can become life-threatening within hours. The effect profile is fully documented and surprising in no respect.
Documented in clinical studies and approval data:
- Hypoglycemia: by far the most frequent and most dangerous documented adverse effect, a direct consequence of the mechanism. Early symptoms are tremor, cold sweat, racing heartbeat, pallor, ravenous hunger and restlessness. Later come impaired concentration, visual disturbance, slurred speech, aggressive or confused behaviour. At the end stand seizure, unconsciousness and death. With an analogue that starts working in 15 minutes the progression is fast. Rapidly absorbed carbohydrates (glucose tablets, juice, soft drink) must be within reach before the needle goes in, not afterwards. Never use alone, never without a blood glucose meter, never without a person present who knows what to do.
- Intracellular potassium shift: insulin drives potassium from the extracellular space into the cell via the sodium-potassium ATPase. Serum potassium falls. The effect is so reliable that insulin is used clinically on purpose to lower elevated potassium. Relevant hypokalemia presents as muscle weakness, cramps and above all cardiac arrhythmia. At high doses hypokalemia is an independent cause of death, separate from blood glucose.
- Timing mismatch: the short profile cuts both ways. If carbohydrate intake after the injection is delayed, skipped or slowly absorbed, the insulin action runs into a void and hypoglycemia lands right in the 1-to-2-hour peak. Conversely, with high-fat or high-protein meals the 3-to-5-hour duration can be too short and glucose climbs again late.
- Loss of warning symptoms: after repeated hypoglycemic events counter-regulation blunts, the early warning symptoms drop out and the first noticed stage is already confusion. Alcohol, beta blockers and physical exertion amplify both the glucose drop and the masking of symptoms.
- Injection site reactions: lipohypertrophy, lipoatrophy, redness, itching and local induration are documented. Hardened areas absorb unpredictably, which can both blunt the effect and unexpectedly accelerate it. Systematic rotation of the injection site is standard in every protocol.
- Weight gain and edema: an increase in body weight belongs to the known profile of any insulin therapy. Sodium retention with peripheral edema is documented particularly at the start.
- Risk of mix-up: insulins differ in concentration (U-100 versus U-200 and higher) and in action profile. Mixing up concentration, syringe type or fast versus slow insulin is one of the best documented error sources in the field. A U-100 syringe used with a more concentrated solution delivers a multiple of the intended dose.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer. If severe hypoglycemia is suspected, particularly with confusion or clouded consciousness, calling emergency services is the only correct response.
Studies
- [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin - Diabetes 1994, Howey et al: glucose clamp comparison against regular human insulin, serum insulin peak more than twice as high and reached in less than half the time.
- Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment - Diabetes 1997, Anderson et al (Multicenter Insulin Lispro Study Group): crossover trial with 1,008 participants, flatter postprandial rise and around 12 percent fewer hypoglycemic episodes versus regular human insulin.
- Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes - Diabetes Care 1998, Brunelle et al: eight trials, over 1,400 patient-years, lower rate of severe hypoglycemia on lispro (3.1 versus 4.4 percent of patients).
- [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia - Clinical Pharmacology and Therapeutics 1995, Howey et al: equal or slightly better glucose control at an average 22.5 minutes before the meal versus 63.8 minutes for regular human insulin.
- Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin - Diabetes Care 1997, Ebeling et al: the advantage of the fast bolus insulin only shows once basal coverage is adjusted - lispro does not replace basal insulin.
